Literature DB >> 30836062

Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells.

Tadahiro Kobayashi1, Kyosuke Oishi1, Ai Okamura2, Shintaro Maeda1, Akito Komuro2, Yasuhito Hamaguchi1, Manabu Fujimoto3, Kazuhiko Takehara1, Takashi Matsushita4.   

Abstract

In tumor immunity, the participation of IL-10-producing regulatory B cells (Bregs), which play an important role in suppressing immune responses, is unclear. In this study, we demonstrated an increase in B16F10 melanoma growth and a decrease in the proportion of IFN-γ- and TNF-α-secreting tumor-infiltrating CD8+ T cells in B cell-specific PTEN-deficient mice in which Bregs were expanded. The number of tumor-infiltrating Bregs significantly increased in B cell-specific PTEN-deficient mice. More than 50% of tumor-infiltrating B cells consisted of Bregs, predominantly CD19+CD5+CD43+ B1a Bregs, in both B cell-specific PTEN-deficient and control mice. Adoptive B1a B cell transfer, which includes >30% of Bregs, increased melanoma growth, whereas non-B1a B cell transfer, which includes <2% of Bregs, exhibited no effect. In addition, adoptive transfer of B1a B cells from wild-type mice, but not IL-10-/- mice, exacerbated B16F10 melanoma growth. The current study indicates that B1a Bregs negatively regulate anti-melanoma immunity by producing IL-10 and reducing T helper 1 type cytokine production in tumor-infiltrating CD8+ T cells. Therefore, B1a Bregs can be a potentially novel target for immunotherapy of melanomas.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30836062     DOI: 10.1016/j.jid.2019.02.016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Skin-Homing Regulatory B Cells Required for Suppression of Cutaneous Inflammation.

Authors:  Lazaro Emilio Aira; Gudrun Fiona Debes
Journal:  J Invest Dermatol       Date:  2021-02-09       Impact factor: 7.590

2.  Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer.

Authors:  Lu Zhang; A Ali Zirakzadeh; Jesper Rosvall; Mats Hedlund; Ping Sheng Hu; Katrine Riklund; Amir Sherif; Ola Winqvist
Journal:  Investig Clin Urol       Date:  2020-12-10

Review 3.  Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection.

Authors:  Yoshiko Matsuda; Takahisa Hiramitsu; Xiao-Kang Li; Takeshi Watanabe
Journal:  Pathogens       Date:  2020-12-23

Review 4.  B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

Authors:  Zena N Willsmore; Robert J Harris; Silvia Crescioli; Khuluud Hussein; Helen Kakkassery; Deepika Thapa; Anthony Cheung; Jitesh Chauhan; Heather J Bax; Alicia Chenoweth; Roman Laddach; Gabriel Osborn; Alexa McCraw; Ricarda M Hoffmann; Mano Nakamura; Jenny L Geh; Alastair MacKenzie-Ross; Ciaran Healy; Sophia Tsoka; James F Spicer; Sophie Papa; Linda Barber; Katie E Lacy; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

Review 5.  Human cutaneous B cells: what do we really know?

Authors:  Irina Lerman; Drew C Mitchell; Christopher T Richardson
Journal:  Ann Transl Med       Date:  2021-03

6.  Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.

Authors:  Byong H Kang; Noor Momin; Kelly D Moynihan; Murillo Silva; Yingzhong Li; Darrell J Irvine; K Dane Wittrup
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

7.  Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.

Authors:  Lena Margarethe Wulfken; Jürgen Christian Becker; Rami Hayajneh; Annette Doris Wagner; Katrin Schaper-Gerhardt; Nina Flatt; Imke Grimmelmann; Ralf Gutzmer
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

Review 8.  Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses.

Authors:  Fabian Flores-Borja; Paul Blair
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

9.  Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.

Authors:  Jinming Yang; Chi Yan; Anna E Vilgelm; Sheau-Chiann Chen; Gregory D Ayers; Christopher A Johnson; Ann Richmond
Journal:  Cancer Immunol Res       Date:  2020-11-11       Impact factor: 12.020

Review 10.  Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Zhou Ran; Luo Yue-Bei; Zeng Qiu-Ming; Yang Huan
Journal:  Front Immunol       Date:  2020-08-20       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.